Clinical Study Randomized Controlled Trial of Strain-specific Probiotic Formulation (renadyl) in Dialysis Patients

Background. Primary goal of this randomized, double-blind, placebo-controlled crossover study of Renadyl in end-stage renal disease patients was to assess the safety and efficacy of Renadyl measured through improvement in quality of life or reduction in levels of known uremic toxins. Secondary goal was to investigate the effects on several biomarkers of inflammation and oxidative stress. Methods. Two 2-month treatment periods separated by 2-month washout and crossover, with physical examinations, venous blood testing, and quality of life questionnaires completed at each visit. Data were analyzed with SAS V9.2. Results. 22 subjects (79%) completed the study. Observed trends were as follows (none reaching statistical significance): decline in WBC count (−0.51 × 109/L, P = 0.057) and reductions in levels of C-reactive protein (−8.61 mg/L, P = 0.071) and total indoxyl glucuronide (−0.11 mg%, P = 0.058). No statistically significant changes were observed in other uremic toxin levels or measures of QOL. Conclusions. Renadyl appeared to be safe to administer to ESRD patients on hemodialysis. Stability in QOL assessment is an encouraging result for a patient cohort in such advanced stage of kidney disease. Efficacy could not be confirmed definitively, primarily due to small sample size and low statistical power—further studies are warranted.

[1]  L. Vitetta,et al.  From the Gastrointestinal Tract (GIT) to the Kidneys: Live Bacterial Cultures (Probiotics) Mediating Reductions of Uremic Toxin Levels via Free Radical Signaling , 2013, Toxins.

[2]  E. Friedman,et al.  Dose Escalation, Safety and Impact of a Strain-Specific Probiotic (Renadyl™) on Stages III and IV Chronic Kidney Disease Patients , 2013 .

[3]  J. Coresh,et al.  Lifetime incidence of CKD stages 3-5 in the United States. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  B. Stecher,et al.  The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. , 2013, Kidney international.

[5]  L. Vitetta,et al.  Uremia and chronic kidney disease: the role of the gut microflora and therapies with pro- and prebiotics. , 2013, Molecular nutrition & food research.

[6]  F. Pezzuto,et al.  Clinical and experimental use of probiotic formulations for management of end-stage renal disease: an update , 2013, International Urology and Nephrology.

[7]  S. Ossareh,et al.  Relation between pretransplant serum levels of soluble CD30 and acute rejection during the first 6 months after a kidney transplant. , 2013, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[8]  H. Steen,et al.  Carbamylation of Serum Albumin as a Risk Factor for Mortality in Patients with Kidney Failure , 2013, Science Translational Medicine.

[9]  G. Andersen,et al.  Chronic kidney disease alters intestinal microbial flora. , 2013, Kidney international.

[10]  Sonia Y. Velásquez,et al.  Alloantigen-stimulated induction and release of CD30 in patients with end-stage renal failure. , 2012, Human immunology.

[11]  N. Ranganathan,et al.  Probiotics, Prebiotics, and Synbiotics: Gut and Beyond , 2012, Gastroenterology research and practice.

[12]  J. Gordon,et al.  Diversity, stability and resilience of the human gut microbiota , 2012, Nature.

[13]  J. Nicholson,et al.  Host-Gut Microbiota Metabolic Interactions , 2012, Science.

[14]  Bernard Henrissat,et al.  Metabolic Reconstruction for Metagenomic Data and Its Application to the Human Microbiome , 2012, PLoS Comput. Biol..

[15]  E. Quigley.  Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults. , 2012, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[16]  T. Meyer,et al.  Colonic contribution to uremic solutes. , 2011, Journal of the American Society of Nephrology : JASN.

[17]  A. Darzi,et al.  Gut microbiome-host interactions in health and disease , 2011, Genome Medicine.

[18]  I-Wen Wu,et al.  p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  E. Friedman,et al.  Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease , 2010, Advances in therapy.

[20]  B. Finlay,et al.  Gut microbiota in health and disease. , 2010, Physiological reviews.

[21]  O. Ayodele,et al.  Burden of chronic kidney disease: an international perspective. , 2010, Advances in chronic kidney disease.

[22]  R. Vanholder,et al.  The Gut: The Forgotten Organ in Uremia? , 2010, Blood Purification.

[23]  E. Friedman,et al.  Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada , 2009, Current medical research and opinion.

[24]  D. Dilillo,et al.  Probiotics in Clinical Practice: An Overview , 2008, The Journal of international medical research.

[25]  N. Pace,et al.  Gastrointestinal microbiology enters the metagenomics era , 2008, Current opinion in gastroenterology.

[26]  D. Grekas,et al.  Increase in Oxidative Stress but Not in Antioxidant Capacity with Advancing Stages of Chronic Kidney Disease , 2007, American Journal of Nephrology.

[27]  M. Pop,et al.  Metagenomic Analysis of the Human Distal Gut Microbiome , 2006, Science.

[28]  K. A. Malik,et al.  Probiotics and their fermented food products are beneficial for health , 2006, Journal of applied microbiology.

[29]  M. Perazella,et al.  Increased Mortality in Chronic Kidney Disease: A Call to Action , 2006, The American journal of the medical sciences.

[30]  P. Stenvinkel.  Inflammation in end‐stage renal disease: The hidden enemy (Review Article) , 2006, Nephrology.

[31]  J. Cutler,et al.  Leading causes of death in the United States. , 2006, JAMA.

[32]  W. Verstraete,et al.  In Vitro and In Vivo Assessment of Intraintestinal Bacteriotherapy in Chronic Kidney Disease , 2006, ASAIO journal.

[33]  T. Meyer,et al.  Removal of P-cresol sulfate by hemodialysis. , 2005, Journal of the American Society of Nephrology : JASN.

[34]  E. Friedman,et al.  Probiotic Amelioration of Azotemia in 5/6th Nephrectomized Sprague-Dawley Rats , 2005, TheScientificWorldJournal.

[35]  R. Barrangou,et al.  Complete genome sequence of the probiotic lactic acid bacterium Lactobacillus acidophilus NCFM. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Cañadillas,et al.  Importance of arachidonic acid as a mediator of parathyroid gland response. , 2003, Kidney international. Supplement.

[37]  R. Vanholder,et al.  New insights in uremic toxins. , 2003, Kidney international. Supplement.

[38]  N. D. de Roos,et al.  Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998. , 2000, The American journal of clinical nutrition.

[39]  R. Foley,et al.  Epidemiology of cardiovascular disease in chronic renal disease , 2000 .

[40]  J. Ayres,et al.  Effect of Oral Administration of Freeze-Dried Lactobacillus acidophilus on Small Bowel Bacterial Overgrowth in Patients with End Stage Kidney Disease: Reducing Uremic Toxins and Improving Nutrition , 1998 .

[41]  T. Chang,et al.  Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats , 1996, Nature Medicine.

[42]  G R Gibson,et al.  Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. , 1995, The Journal of nutrition.

[43]  Michael Warner,et al.  Learning Who We Are , 1991 .

[44]  H. Akaike.  A new look at the statistical model identification , 1974 .

[45]  K. Taki,et al.  Indoxyl sulfate-lowering capacity of oral sorbents affects the prognosis of kidney function and oxidative stress in chronic kidney disease. , 2007, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[46]  Sudhir V. Shah,et al.  Oxidants in chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[47]  R. Palmquist.  A Preliminary Clincial Evaluation of Kibow Biotics , ® a Probiotic Agent , on Feline Azotemia , 2006 .

[48]  K. Shahani,et al.  Delineation of Beneficial Characteristics of Effective Probiotics , 2000 .

[49]  Dunn,et al.  Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. , 1996, Mineral and electrolyte metabolism.

[50]  M. Hagiage.  [Intestinal flora]. , 1993, Annales de gastroenterologie et d'hepatologie.